Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

The Nanoparticle-Mediated Delivery of Therapeutic Sirnas Targeting the KMT2A::Afdn Fusion Gene in AML

Manisha du Plessis, Luis Daniel Mata Casimiro, Irmela Jeremias, Olaf Heidenreich

Blood (2024) 144 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2024-202373

Published: 2024

Journal Articles

ALL-R: An Anchoring Score to Predict Relapse in Acute Lymphoblastic Leukemia (ALL) Using a Zebrafish Patient-Derived Xenograft Model

Anja Arner, Bradley Wayne Blaser, Andreas Ettinger, Bettina Schmid, Irmela Jeremias, Vera Binder-Blaser

Blood (2024) 144 (Supplement 1): 275.

https://doi.org/10.1182/blood-2024-209569

Published: 2024

Journal Articles

Serially Transplantable, Genetically Modified Patient Derived Xenograft Models of Acute Myeloid Leukemia Represent Primary Patients' Cells and Enable Reliable and Reproducible Preclinical Therapy Trials

Blood (2024) 144 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2024-198652

Published: 2024

Journal Articles

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2024-207274

Published: 2024

Journal Articles

Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Blood (2024) 144 (Supplement 1): 1392.

https://doi.org/10.1182/blood-2024-206832

Published: 2024

Journal Articles

High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Alisa Maier, Lukas Ulrich, Binje Vick, William David Keay, Johannes Adrian Hildebrand, Carolin Dorothea Strobl, Verena Passerini, Louisa Adolph, Michael Heide, Tabea Felicitas Freyholdt, Gerulf Hänel, Axel Lechner, Susanne Thieme, Leon Kaulen, Louisa von Baumgarten, Daniel J Hodson, Martina Rudelius, Irmela Jeremias, Oliver Weigert

Blood (2024) 144 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2024-194493

Published: 2024

Journal Articles

Transcriptional control of leukemogenesis by the chromatin reader SGF29

Blood (2024) 143 (8): 697–712.

https://doi.org/10.1182/blood.2023021234

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

Blood (2023) 141 (9): 1023–1035.

https://doi.org/10.1182/blood.2021015246

Published: 2023

Includes: Supplemental data

Journal Articles

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias

Blood (2023) 141 (8): 955–960.

https://doi.org/10.1182/blood.2022016411

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Blood (2022) 140 (24): 2594–2610.

https://doi.org/10.1182/blood.2021014241

Published: 2022

Includes: Supplemental data

Journal Articles

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Daniel Bergér, Steffen Dickopf, Binje Vick, Katharina Weinlich, Irmela Jeremias, Ulrich Brinkmann, Christoph Klein

Blood (2022) 140 (Supplement 1): 2249–2250.

https://doi.org/10.1182/blood-2022-163104

Published: 2022

Journal Articles

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

Sebastian E. Koschade, Kevin Klann, Shabnam Shaid, Binje Vick, Jan A. Stratmann, Marlyn Thölken, Laura M. Meyer, The Duy Nguyen, Julia Campe, Laura M. Moser, Susanna Hock, Fatima Baker, Christian Meyer, Frank Wempe, Hubert Serve, Evelyn Ullrich, Irmela Jeremias, Christian Münch, Christian H. Brandts

Blood (2022) 140 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2022-168824

Published: 2022

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

WT1 and DNMT3A Play an Essential Function and Represent Therapeutic Vulnerabilities in Certain AML Samples, As Shown By CRISPR/Cas9 Mediated Knockout in PDX Models In Vivo

Maryam Ghalandary, Yuqiao Gao, Martin Becker, Diana Amend, Klaus H. Metzeler, Maja Rothenberg-Thurley, Irmela Jeremias

Blood (2021) 138 (Supplement 1): 377.

https://doi.org/10.1182/blood-2021-150305

Published: 2021

Journal Articles

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Ehsan Bahrami, Jan Philipp Schmid, Martin Becker, Anna-Katharina Wirth, Rupert Öllinger, Roland Rad, Binje Vick, Ashok Kumar Jayavelu, Matthias Mann, Tobias Herold, Irmela Jeremias

Blood (2021) 138 (Supplement 1): 708.

https://doi.org/10.1182/blood-2021-149658

Published: 2021

Journal Articles

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2021-148429

Published: 2021

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

Dana Stenger, Tanja A. Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G. P. Grünewald, Sebastian Kobold, Dirk H. Busch, Irmela Jeremias, Franziska Blaeschke, Tobias Feuchtinger

Blood (2020) 136 (12): 1407–1418.

https://doi.org/10.1182/blood.2020005185

Published: 2020

Includes: Supplemental data

Journal Articles

A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo

Ehsan Bahrami, PhD, Martin Becker, PhD, Anna-Katharina Wirth, MSc, Jan Phillip Schmid, MSc, Tobias Herold, MD, Rupert Öllinger, PhD, Roland Rad, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 3945.

https://doi.org/10.1182/blood-2019-124288

Published: 2019

NARROW

The Nanoparticle-Mediated Delivery of Therapeutic Sirnas Targeting the KMT2A::Afdn Fusion Gene in AML

ALL-R: An Anchoring Score to Predict Relapse in Acute Lymphoblastic Leukemia (ALL) Using a Zebrafish Patient-Derived Xenograft Model

Serially Transplantable, Genetically Modified Patient Derived Xenograft Models of Acute Myeloid Leukemia Represent Primary Patients' Cells and Enable Reliable and Reproducible Preclinical Therapy Trials

Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Transcriptional control of leukemogenesis by the chromatin reader SGF29

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

WT1 and DNMT3A Play an Essential Function and Represent Therapeutic Vulnerabilities in Certain AML Samples, As Shown By CRISPR/Cas9 Mediated Knockout in PDX Models In Vivo

In Vivo CRISPR-Cas9 Screens in PDX Models Reveals ADAM10 As Novel Therapeutic Target in Acute Leukemia

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR

A CRISPR/Cas9 Library Screen in Patients' Leukemia Cells In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only